The medicines that Americans rely on every day are often products of complex global supply chains, which offer efficiency but also come with vulnerabilities due to geopolitical risks and regulatory challenges. The Duke-Margolis Institute for Health Policy has released a new white paper to discuss opportunities to improve drug supply chains. This paper provides recommendations for policymakers to pursue international collaborations as a complement to onshoring efforts to achieve a secure, resilient, and efficient supply chain that gets patients the medicines they need.
Read the two-page executive summary here.